ReCode Therapeutics, a company specializing in genetic medicine, has initiated a Phase 1 clinical trial for RCT2100, an innovative inhaled treatment for cystic fibrosis (CF).

The study focused on the use of paxalisib, an oral medication that inhibits both PI3K and mTOR, alongside radiation therapy for patients with brain metastases from solid tumors that have a PI3K pathway mutation.

Lutris Pharma has published positive results from a phase 1/2 clinical trial of their lead compound, LUT014.

Sairiyo Therapeutics Inc., has begun regulatory and clinical development to assess the potential of its patented enteric-coated cepharanthine (PD-001) for treating oncology and infectious diseases.

May 23rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Ionis Pharmaceuticals, Inc. reported favorable primary results from the HALOS Phase 1/2a open-label trial of ION582 for Angelman syndrome.

May 22nd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Early findings from a study involving 472 infants aged nine months show that a new vaccine candidate, Shigella4V (S4V), developed by LimmaTech, has a good safety record and is well tolerated.

Ashvattha Therapeutics has enrolled its first patient in an expanded Phase 1/2 trial of 18F-OP-801, an imaging agent designed to cross the blood-brain barrier and target neuroinflammation.

A clinical trial is currently underway to evaluate the combination treatment of BNT316/ONC-392, an anti-CTLA-4 antibody, with lutetium (177Lu) vipivotide tetraxetan (Pluvicto®).

Biotechnology firm Ocugen, Inc. has reached a significant milestone in its clinical trial for a gene therapy treatment, OCU410ST, aimed at Stargardt disease.

Biotechnology firm Celcuity Inc. has initiated a Phase 1b/2 clinical trial, known as CELC-G-201, to test the efficacy and safety of gedatolisib combined with Nubeqa® (darolutamide).